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Objectives. The purpose of this study was to compare 3-year
risk-adjusted survival in patients undergoing coronary artery
bypass graft (CABG) surgery and percutaneous transluminal
coronary angioplasty.
Background. Coronary artery bypass graft surgery and angio-
plasty are two common treatments for coronary artery disease.
For referral purposes, it is important to know the relative pattern
of survival after hospital discharge for these procedures and to
identify patient characteristics that are related to survival.
Methods. New York’s CABG surgery and angioplasty regis-
tries were used to identify New York patients undergoing
CABG surgery and angioplasty from January 1, 1993 to De-
cember 31, 1995. Mortality within 3 years of undergoing the
procedure (adjusted for patient severity of illness) and subse-
quent revascularization within 3 years were captured. Three-
year mortality rates were adjusted using proportional hazards
methods to account for baseline differences in patients’ severity
of illness.
Results. Patients with one-vessel disease with the one vessel not
involving the left anterior descending artery (LAD) or with less
than 70% LAD stenosis had a statistically significantly longer
adjusted 3-year survival with angioplasty (95.3%) than with CABG
surgery (92.4%). Patients with proximal LAD stenosis of at least
70% had a statistically significantly longer adjusted 3-year sur-
vival with CABG surgery than with angioplasty regardless of the
number of coronary vessels diseased. Also, patients with three-
vessel disease had a statistically significantly longer adjusted
3-year survival with CABG surgery regardless of proximal LAD
disease. Patients with other one-vessel or two-vessel disease had
no treatment-related differences in survival.
Conclusions. Treatment-related survival benefit at 3-years in
patients with ischemic heart disease is predicted by the anatomic
extent and specific site of the disease, as well as by the treatment
chosen.
(J Am Coll Cardiol 1999;33:63–72)
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Coronary artery bypass graft (CABG) surgery and percutane-
ous transluminal coronary angioplasty were developed nearly
30 years and 20 years ago, respectively, as alternatives to
medical therapy for the treatment of patients with coronary
artery disease (1,2).
In recent years, several studies have examined the bene-
fits of these two interventions relative to medical therapy
and/or to one another (3–9). For the most part the studies
that have compared CABG surgery and angioplasty have not
found significant long-term mortality differences. However,
with the exception of a single institution study by Jones et al.
(7), these studies have grouped patients for analysis only on
the basis of the number of diseased coronary arteries. As has
been pointed out many years ago by Favaloro (10) and by
Ringqvist et al. (11), another important anatomic consider-
ation in the prognosis for patients with ischemic heart
disease is the location of the lesion, both with respect to the
vessel in which it is located and the location within the
vessel. It is likely that a major reason why lesion location
was not used in other studies was the limited number of
patients in these studies, most of which were randomized
clinical trials.
This study uses prospectively defined data from New York
State cardiac procedure registries in conjunction with mortality
information from the state’s Vital Statistics data system to
compare 3-year outcomes for CABG surgery and angioplasty
for nearly 30,000 patients undergoing each of the interven-
tions. The purpose of studying this large population was to
identify preoperative clinical and angiographic variables that
predicted differences in survival among CABG surgery and
angioplasty patients and, in particular, to control for lesion
location when assessing differences.
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Methods
Study population. Patients in the study consisted of those
patients who were New York residents who underwent isolated
CABG surgery (CABG surgery with no other major open heart
procedures in the same admission) or angioplasty between
1/1/93 and 12/31/95 in New York, who had no previous
revascularization, did not have left main disease (defined as
stenosis .50%) and did not suffer an acute myocardial infarc-
tion during the 24-h period prior to undergoing revasculariza-
tion.
Two registries in New York State, the Cardiac Surgery
Reporting System (CSRS) and the Coronary Angioplasty
Reporting System (CARS), are the sources of the patients in
the study. These systems include numerous patient risk factors;
admission, surgery and discharge dates, and discharge status.
With the exception of some additional lesion-specific infor-
mation in CARS, the registries contain exactly the same data
elements and definitions. Also, the same process was used to
train the 31 hospital cardiac surgery departments responsible
for coding the CSRS forms and the 32 hospital cardiac
catheterization laboratories responsible for coding the CARS
forms to capture the relevant information. When data fields
are found to be missing, hospitals are contacted and asked to
complete the missing information. Also, comprehensive audits
of approximately half of the hospitals in each registry are
conducted each year, and several hospitals have been asked to
recode all or part of their data as a result of the audits.
Since patients are identified using social security numbers,
subsequent revascularizations (CABG surgery or angioplasty)
for each patient within New York State can be tracked using
the two registries. Patient deaths outside of the hospital, or in
the hospital for patients whose subsequent admission is not for
the purpose of undergoing CABG surgery or angioplasty,
cannot be identified using the registries. However, New York
has a vital statistics death file that identifies all residents of the
state who have died in each year, and this was linked to the two
registries using patient social security numbers. Since this file is
limited to New York residents, the study was also limited to
this group.
The study was limited to patients who underwent CABG
surgery or angioplasty after 1/1/93, because the CABG surgery
registry did not contain information on detailed locations of
coronary lesions (e.g., in the proximal left anterior descending
artery) until 1993.
This approach led to the identification of 29,646 CABG
surgery patients from the 31 hospitals in the state in which
CABG surgery is performed and 29,930 angioplasty patients
from the 32 hospitals in the state in which angioplasty is
performed. A total of 2,552 patients from out of state or whose
residence was unknown who underwent CABG surgery or
angioplasty in New York during the same time period were not
included in the study.
Each patient was classified into one of eight anatomic
groups based on the number of vessels diseased (using $70%
stenosis), whether there is significant disease in the left ante-
rior descending artery (LAD) and if there is, whether it is in
the proximal region.
Study end points. Patients in the study were tracked to
determine if they died at any time during the study period, and
if so, how long they lived after undergoing the procedure.
Deaths during the same admission as the procedure were
identified using the registries, and deaths after discharge
following the procedure were identified using the death file. In
both cases, the time between the date of the procedure and the
date of death was also noted.
Similarly, all subsequent patient revascularizations (one or
more CABG operations and/or angioplasties subsequent to
the index procedure in the time period of interest) were
captured by linking the registries using patient social security
number as the primary key. All four combinations of the initial
procedure and the revascularization procedure (CABG sur-
gery/subsequent CABG surgery; initial angioplasty/subsequent
CABG surgery; etc.) were examined. Note that if a patient
underwent a second procedure in the hospital after the index
procedure, it is reflected in these analyses as a subsequent
revascularization, as well as procedures that were performed in
later visits to a hospital.
Data analysis. The first analyses consisted of examining,
for both the CABG surgery and the angioplasty populations,
the prevalence rates for all important determinants of short-
and long-term survival such as the number of vessels diseased,
patient age and gender, a variety of comorbidities and mea-
sures of the patient’s hemodynamic state and ventricular
function.
Initial comparisons of mortality rates and subsequent re-
vascularization rates among CABG surgery and angioplasty
patients consisted of computing these rates for several time
periods (in-hospital, 6 months, 1 year, 2 years, 3 years) for the
different anatomic groups. It is important to note that in the
analysis of “subsequent revascularization” rates, the first pro-
cedure performed defined the treatment group regardless of
how many or what kind of subsequent revascularizations there
were. In the mortality analyses, patients who underwent
CABG surgery subsequent to angioplasty in the index admis-
sion were regarded as CABG surgery patients. The analyses
were then repeated with the “intention-to-treat” principle, in
which patients were permanently assigned to the initial proce-
dure performed.
Next, 3-year survival for the two procedures was compared
while controlling for differences in patient severity of illness
using Cox proportional hazards models. A different model was
used for each of the coronary anatomy groups defined above.
The SAS procedure PHREG (Version 6.12) was used with a
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft
CARS 5 Coronary Angioplasty Reporting System
CHF 5 congestive heart failure
CSRS 5 Cardiac Surgery Reporting System
LAD 5 left anterior descending artery
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stepwise approach that retains only the significant predictors of
survival. Candidate independent variables in each of the
stepwise analyses included all the demographic and clinical
variables available in the two registries. As a second approach,
all demographic and clinical variables were retained in the
models for all coronary anatomy groups.
The Cox models were first used to compare relative differ-
ences between CABG surgery mortality and angioplasty mor-
tality for each anatomic group by computing a hazard ratio,
which is the ratio of the mortality of CABG surgery to the
mortality of angioplasty at any given point in time, controlling
for differences in the covariates (patient risk factors). First,
stepwise models were developed for predicting survival using
the patient risk factors. Then, the type of revascularization
(CABG surgery or angioplasty, with CABG surgery coded as a
1 and angioplasty coded as a 0) was added to the models to
determine if survival was dependent on the type of intervention
while controlling for significant patient risk factors. The expo-
nential of the coefficient of this variable in the Cox model is the
hazard ratio for CABG surgery: angioplasty.
Also, 95% confidence intervals for the hazard ratios were
calculated to test for significant differences in survival between
CABG surgery and angioplasty, and then logarithms of the
ratios and their confidence intervals were computed so that
intervals on either side of 1.0 (0.0 for the logarithm) would
have lengths that were comparable. An interval whose upper
limit is below 1 (below 0 in the log scale) denotes that adjusted
mortality is significantly lower for CABG surgery; an interval
whose lower limit lies above 1 (above 0 in the log scale)
indicates that the adjusted mortality is statistically significantly
higher for CABG surgery patients (significantly lower for
angioplasty patients). Note that, primarily because of operative
mortality differences between CABG surgery and angioplasty,
the CABG surgery: angioplasty hazard ratio is not constant
over time, so that the estimate of the treatment effect is an
average hazard ratio.
To measure survival differences between CABG surgery
and angioplasty in percentages rather than in relative terms for
each anatomic subgroup, a Cox proportional hazards model
for the subgroup was used to construct adjusted Kaplan–Meier
survival curves for CABG patients and for angioplasty patients.
In contrast to the analyses of relative survival described above,
treatment (angioplasty or CABG surgery) was used as a
stratification factor instead of a modeled covariate, so that
there was no need to assume that the proportional hazards
assumption of the Cox models was true for the treatment
variable.
For each anatomic subgroup, a survival curve for CABG
surgery was calculated for each individual patient who under-
went CABG surgery, and these curves were averaged across all
patients undergoing CABG surgery within the subgroup to
obtain a single survival curve. The process was then repeated
Table 1. Risk Factors of Patients Undergoing CABG Surgery or Angioplasty for the First Time, in
New York: 1993–1995
Risk Factor
% of CABG Surgery
Patients With Risk
Factor (n 5 29,646)
% of Angioplasty Patients
With Risk Factor
(n 5 29,930) p Value
Age (yr) , 0.001
,55 16.95 29.47
55 to 64 26.59 28.26
65 to 74 38.24 29.19
75 to 84 17.31 12.06
$85 0.91 1.02
Female gender 28.58 31.99 , 0.001
Ejection fraction , 0.001
Less than 20 1.45 0.41
Between 20 and 29 7.08 1.43
Between 30 and 39 14.93 4.84
Previous MI between 1 and 7 days 10.10 17.90 , 0.001
Stroke 5.27 2.13 , 0.001
Carotid/cerebrovascular disease 10.58 2.38 , 0.001
Aortoiliac disease 5.25 3.03 , 0.001
Femoral/popliteal disease 10.94 4.15 , 0.001
Hemodynamically unstable 2.80 0.83 , 0.001
Shock 0.37 0.20 , 0.001
ECG evidence of LVH 11.79 6.11 , 0.001
Persistent ventrical arrhythmia 3.02 1.51 , 0.001
COPD 15.11 4.31 , 0.001
CHF 10.48 3.60 , 0.001
Diabetes requiring medication 27.28 17.36 , 0.001
Renal failure 2.75 1.45 , 0.001
CHF 5 congestive heart failure; COPD 5 chronic obstructive pulmonary disease; ECG 5 electrocardiographic;
LVH 5 left ventricular hypertrophy; MI 5 myocardial infarction.
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for angioplasty patients in the anatomic subgroup. The result-
ing two curves were then plotted for each anatomic subgroup
so that the absolute numerical differences in survival between
CABG surgery and angioplasty, controlling for baseline differ-
ences in patient risk factors, could be viewed for each point in
time. For each anatomic subgroup, the adjusted survival
percentages represent an estimate of what the survival would
have been if all patients in the group had undergone CABG
surgery, and likewise if all patients had undergone angioplasty.
Consequently, differences in preoperative risk between CABG
surgery patients and angioplasty patients have been controlled
for as much as possible. For each anatomic subgroup, a
chi-square test was used to test for differences in 3-year
survival among patients undergoing the two procedures.
In a second set of models for each of the anatomic groups,
interactions between type of intervention and the significant
risk factors in the initial models were added to the original risk
factors to determine if there were certain types of patients for
whom one of the interventions was particularly preferable.
This type of analysis is especially useful when no mortality
differences are found among the entire population of patients
being considered, but there are significant survival differences
for some subgroup (e.g., diabetic subjects).
Results
The observed (unadjusted) in-hospital mortality rate for the
CABG surgery patients in the study was 1.90%, and the
observed in-hospital mortality rate for angioplasty patients in
the study was 0.40%. The 3-year survival rate for all CABG
surgery patients in the study was 91.4%, and the 3-year survival
rate for all angioplasty patients in the study was 94.6%.
Table 1 presents the demographic, clinical and angio-
graphic characteristics of the CABG surgery and angioplasty
patients in the study. Most characteristics are presented as
binary variables (present, not present). For age, ejection
fraction and time since previous myocardial infarction, multi-
ple categories are used. Statistically significant differences in
relative frequencies among CABG surgery and angioplasty
patients are identified using chi-square tests.
As indicated, CABG surgery patients were significantly
older, although there were more angioplasty patients in the 85
and older group, and were significantly more likely to be male.
Also, CABG surgery patients had significantly lower ejection
fractions, and had a significantly higher prevalence of all of the
binary clinical measures. A significantly higher percentage of
angioplasty patients had myocardial infarctions between 1 and
7 days prior to the procedure than CABG patients.
Figure 1 presents, for CABG surgery and angioplasty, the
percentage of patients who underwent one or more subsequent
revascularizations by type of revascularization. Of the angio-
plasty patients, 10.4% underwent subsequent CABG surgery
and 26.6% underwent repeat angioplasties in the 3-year pe-
riod. Of the CABG surgery patients, 0.5% underwent subse-
quent CABG surgery and 2.8% underwent subsequent angio-
plasties in the 3-year period.
The eight proportional hazards models developed for the
purpose of risk-adjusting long-term mortality (not presented
here for the sake of brevity) yielded between five and 12
significant preprocedural risk factors. Risk factors that proved
Figure 1. Percentage of patients undergoing a second revasculariza-
tion procedure within 4 years. CABG 5 coronary artery bypass graft;
PTCA 5 percutaneous transluminal coronary angioplasty.
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to be significant in five or more of the models were age and
renal failure (all eight models), chronic obstructive pulmonary
disease, congestive heart failure (CHF) and diabetes (seven
models), ejection fraction (six models) and femoral/popliteal
disease (five models).
Table 2 presents, for each of the eight anatomic groups, the
number of patients undergoing CABG surgery and angioplasty
between 1993 and 1995, the observed 3-year survival and the
adjusted 3-year survival (based on the proportional hazards
model for that anatomic group). Also, p values are provided
for tests of the differences in 3-year adjusted survival between
CABG surgery and angioplasty. The table demonstrates that
there are statistically significant 3-year survival differences for
five of the anatomic groups. For patients with one-vessel
disease/no LAD, angioplasties had a statistically significantly
higher 3-year adjusted survival than CABG surgery (95.3% vs.
92.4%). For patients with one-vessel disease/proximal LAD
and with two-vessel disease/proximal LAD, CABG surgery had
a statistically significantly higher adjusted survival (96.6% vs.
95.2%, and 93.8% vs. 91.7%, respectively). Also, both groups
of patients with three-vessel disease (nonproximal LAD and
proximal LAD) exhibited a statistically significantly higher
survival with CABG surgery (90.3 vs. 86.0 and 90.3 vs. 86.1,
respectively). Note that the relatively low survival rate for
one-vessel disease/no LAD patients undergoing CABG sur-
gery was not related to the 22% of these patients for whom
angioplasties had failed. Their survival rate (94.3%) was
actually higher than the CABG patients in this anatomic group
without failed angioplasties (87.8%).
Figure 2 presents the logarithms of the adjusted hazard
ratios for CABG surgery: angioplasty for each of the eight
anatomic groups. This characterization differs from Table 2 in
that Table 2 presents survival differences after 3 years, whereas
the hazard ratios in Figure 2 represent the logarithms of the
average relative advantage of one intervention compared to
the other over the course of the 3-year period. Statistically
significant relative differences in Figure 2 are represented by
confidence intervals that do not overlap the vertical line at 0.0.
The results in Figure 2 are consistent with the results in Table
2 in that there were statistically significant survival differences
by treatment choice for the same five anatomic groups. Again,
angioplasty had a statistically significantly higher relative sur-
vival for one-vessel disease/no LAD, with an adjusted hazard
ratio of 1.643 (obtained by exponentiating the log scale value
presented in Fig. 2). Coronary artery bypass graft surgery had
a statistically significantly higher relative survival for one-vessel
disease/proximal LAD, two-vessel disease/proximal LAD and
both three-vessel disease groups (with relative hazard ratios of
0.700, 0.695, 0.670 and 0.586, respectively). Identical results
were obtained with respect to significance when the statistical
models were redone using all risk factors rather than retaining
only the significant risk factors in a stepwise analysis.
Figures 3 to 7 present the 3-year adjusted survival curves for
CABG surgery and angioplasty for all five of the eight ana-
Table 2. Three-Year Survival by Treatment in Each Anatomic Subgroup
Coronary Anatomy Group Patients
Observed Survival
(%)
Adjusted Survival
(%) p Value
95% Confidence Interval for
Adjusted Survival Differences
(CABG Surgery 2 PTCA)
One vessel, No LAD
CABG 507 89.2 92.4 0.003 (20.006, 20.052)
PTCA 11,233 95.4 95.3
One vessel, nonproximal LAD
CABG 153 95.8 96.0 0.857 (20.029, 0.035)
PTCA 4,130 95.7 95.7
One vessel, proximal LAD
CABG 1,917 95.8 96.6 0.010 (0.004, 0.024)
PTCA 5,868 95.5 95.2
Two vessel, no LAD
CABG 1,120 91.0 93.0 0.664 (20.014, 0.022)
PTCA 2,729 93.4 92.6
Two vessel, nonproximal LAD
CABG 850 91.3 92.3 0.438 (20.029, 0.013)
PTCA 2,300 93.3 93.1
Two vessel, proximal LAD
CABG 7,242 93.5 93.8 , 0.001 (0.009, 0.033)
PTCA 2,376 92.8 91.7
Three vessel, nonproximal LAD
CABG 1,984 90.1 90.3 0.002 (0.013, 0.073)
PTCA 660 86.7 86.0
Three vessel, proximal LAD
CABG 15,873 90.1 90.3 , 0.001 (0.015, 0.069)
PTCA 634 88.2 86.1
CABG 5 coronary artery bypass graft; LAD 5 left anterior descending artery; PTCA 5 percutaneous transluminal coronary angioplasty.
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tomic groups with statistically significant survival differences.
Note that the 3-year end points match with the 3-year adjusted
survival rates given in Table 2, and that the curves differ only
in that they also provide intermediate adjusted survival rates.
Of particular interest is that one of the curves (Fig. 6) exhibits
a crossover, whereby survival is initially higher for angioplasty
(as a result of the higher procedural mortality rate for CABG
surgery), but that eventually survival becomes higher for
CABG surgery. This anatomic group is three-vessel disease/
nonproximal LAD, for which CABG surgery exhibited a
statistically significantly longer survival on average and at the
end of 3 years. However, angioplasty does have a higher
survival up until about 6 months after the procedure is
performed.
The next step in the analysis plan consisted of investigating,
for each anatomic group, interactions between treatment type
(angioplasty, CABG surgery) and the significant clinical vari-
ables in the proportional hazards model for that group. The
only group for which there was a significant interaction was
two-vessel disease/proximal LAD, for which there was a sig-
nificant interaction between treatment type and CHF. The
direction of the interaction was such that the differential in
survival between CABG surgery and angioplasty patients was
increased even more among patients with CHF.
When the data in Table 2 and Figures 2 to 7 were
recomputed based on the “intention-to-treat” principle, in
which patients were permanently assigned to the first treat-
ment they underwent, the results were essentially the same,
with the same groups exhibiting significant differences.
Discussion
Summary of results and contrast with other studies. This
study has reported on long-term survival differences between
CABG surgery and angioplasty in New York State. Four other
recent studies on this topic were multi-institutional random-
ized trials (3–6), and as reported in the study by Jones et al.
(7), a meta-analysis that combined the results of the first three
of these clinical trials concludes that there is no difference in
total mortality between CABG surgery and angioplasty for
2,794 patients with two- or three-vessel disease. It is very
important to emphasize that none of the randomized clinical
trials distinguished those patients with proximal LAD disease
from patients without proximal LAD disease. In other words,
patients were grouped for analysis only on the basis of number
of vessels diseased, not on the location of the disease.
The aforementioned study by Jones et al., which was based
on the Duke University Registry, and was not a randomized
trial, found no long-term mortality differences between CABG
surgery and angioplasty among all 3,648 two- and three-vessel
disease patients (7). However, when these patients were placed
into subcategories based on degree of stenosis ($75%, $95%)
and the presence of significant lesion in the proximal LAD,
differences in the effectiveness of CABG surgery and angio-
plasty were detected. Specifically, all patients with three-vessel
Figure 2. The 95% confidence interval for Ln (adjusted hazard ratio)
of CABG patient death: PTCA patient death within a 3-year period
(excluding patients with myocardial infarction less than 24 h before
procedure). LAD 5 left anterior descending artery.
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disease and those patients with two-vessel disease/proximal
LAD had statistically significantly longer survival times with
CABG surgery. Patients with one-vessel disease/no LAD had
statistically significantly longer survival times with angioplasty.
Other patients did not have significantly different survival
times for the two procedures.
The results of this study are virtually the same as those in
the Jones et al. study. Again, patients with one-vessel dis-
ease/no LAD had statistically significantly longer survival times
with angioplasty. Also, all patients with three-vessel disease
and patients with two-vessel disease/proximal LAD had statis-
tically significantly longer survival times with CABG surgery.
The one difference was that patients with one-vessel disease/
proximal LAD had statistically significantly longer survival
times with CABG surgery in this study. In the Jones et al.
study, these patients (defined as one-vessel disease/$95%
proximal LAD) were combined with two-vessel disease/no
Figure 3. Adjusted Kaplan–Meier survival curve: CABG versus PTCA
for one-vessel disease/no LAD. Abbreviations as in Figure 2.
Figure 4. Adjusted Kaplan–Meier survival curve: CABG versus PTCA
for one-vessel disease/proximal LAD. Abbreviations as in Figure 2.
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LAD patients, and were found to have longer but not signifi-
cantly longer survival with CABG surgery. When we combined
the two groups and used a 99% confidence interval as Jones et
al. did, we also found that the new group had higher, but not
significantly higher, survival with CABG surgery.
With regard to diabetic patients, the fourth of the clinical
trials mentioned above, the BARI study, found that 5-year
cardiac mortality for CABG surgery was significantly lower
than that for angioplasty, but that there was no statistically
significant difference when the analyses were restricted to
nondiabetic patients. However, there were only 1,476 nondia-
betic patients in the study prior to randomization (6). Also, a
study by Gum et al. that concentrated on diabetic subjects
found that diabetic patients undergoing CABG surgery had
lower 6-year mortality and cardiac event rates than diabetic
patients undergoing angioplasty (12).
In contrast to these findings, we found that there were
Figure 5. Adjusted Kaplan–Meier survival curve: CABG versus PTCA
for two-vessel disease/proximal LAD. Abbreviations as in Figure 2.
Figure 6. Adjusted Kaplan–Meier survival curve: CABG versus PTCA
for three-vessel disease/nonproximal LAD. Abbreviations as in Figure
2.
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statistically significant differences in mortality between patients
undergoing CABG surgery and angioplasty among five of the
eight anatomic groups we studied (with higher survival among
CABG surgery patients for four of the five groups) for all
patients in the study, and that these differences remained when
we restricted the study to nondiabetic subjects. This finding
was further confirmed by the finding that there was no
significant interaction in the proportional hazards models
between treatment type and diabetes.
Caveats. There are several important caveats. First, the
study is not a randomized clinical trial. Consequently, choice of
treatment was influenced by clinicians’ opinions of the “right”
option. We have attempted to minimize the selection bias
introduced by this “reality of practice” by adjusting for differ-
ences among patients in demographics, comorbidities, ventric-
ular function and hemodynamic state. Nevertheless, unmea-
sured differences in patient severity of illness could account for
differences in long-term outcomes between the two competing
interventions. However, the results of this study and of another
nonrandomized study by Jones et al. (7) are sufficiently close to
results emanating from clinical trials to support using obser-
vational database analyses to study the relative effectiveness of
alternative interventions. In fact, given the much larger sample
sizes and much lower costs associated with using observational
databases, registries such as the one in New York State may
serve as an important supplement to randomized clinical trials.
Another important caveat is that, like all studies of this
nature, comparative studies of CABG surgery and angioplasty
can become rapidly outdated in view of evolving improvements
in procedural technology and technique. For example, there
have been refinements in cardiac anesthesia and operative
techniques for CABG surgery, such as the type of cardioplegia
used, the increased use of arterial grafts and the use of
minimally invasive surgery. The increased use of intracoronary
stents for angioplasty patients appears to decrease the resten-
osis rate. Although long-term survival data are not yet avail-
able, it is fair to say that advances in angioplasty in the past 3
to 5 years have been much more dramatic than advances in
CABG surgery. It is therefore possible that future studies will
result in very different conclusions once long-term survival data
for stent patients become available. Note that for the study
period, a total of 3,537 angioplasty patients (11.8%) received
stents, and that the percentage ranged from 10.45% of patients
with three-vessel disease, nonproximal LAD to 15.24% with
two-vessel disease, proximal LAD.
It should also be emphasized that we have reported statis-
tically significant differences, but that these differences may not
be of clinical significance. There are many important consid-
erations in the choice of procedure, including the patient’s life
expectancy and the attitude of the patient toward taking risks.
For example, when the long-term survival curves cross, this
means that one of the procedures is preferable for some period
of short-term survival, and the other is preferable when longer
term survival is used as the criterion. In this study, survival
curves crossed for three-vessel disease/nonproximal LAD (for
which CABG surgery had a statistically significantly longer
adjusted survival, but angioplasty had a higher probability of
short-term survival). Crossovers may occur because of the
higher operative mortality for CABG surgery (leading to lower
short-term survival for CABG surgery) and more complete
Figure 7. Adjusted Kaplan–Meier survival curve: CABG versus PTCA
for three-vessel disease/proximal LAD. Abbreviations as in Figure 2.
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revascularization in CABG patients (leading to higher long-
term survival for CABG patients). A risk-averse patient may
prefer the treatment that has superior short-term survival
(angioplasty in this case) even though the long-term survival is
lower. Consequently, it is preferable to present detailed infor-
mation about the nature of the adjusted survival curves to
patients when the curves cross. An excellent comprehensive
discussion of these issues is presented by Howard et al. (13).
One difference between our study and the ones referenced
above is that we did not include patients who had suffered an
acute myocardial infarction in the 24-h period prior to the
surgery. This group was eliminated from consideration because
it was felt that a higher percentage of salvage patients (whose
true preprocedural risk could not be accurately estimated)
underwent angioplasty. We repeated the study with this group
included and found that all the significant differences in 3-year
mortality reported in the Results section remained, although in
general the survival for CABG surgery improved in relation to
angioplasty survival, presumably because of the salvage group
mentioned above.
Another limitation is that because resources were not
available to follow patients after discharge, we were only able
to capture deaths for New York State residents (using the New
York State death file) and revascularizations that occurred in
New York hospitals (by linking data from the two registries
[i.e., CABG surgery and angioplasty] that were used to obtain
other data in the study). We attempted to minimize the bias
introduced by this limitation by restricting ourselves to patients
residing in New York during the performance of the index
procedure, but we were not able to capture deaths of patients
who moved to another state or subsequent revascularizations
of patients that were performed in another state.
However, we had access to Medicare data (limited to
patients 65 years old and older) from a different time period
(1991–1992) that were compared to Registry data from the
same time period to estimate the deaths missed because of
patients moving out of state. The difference in 3-year survival
between the two databases was only 0.8% (87.6% for Medicare
vs. 88.4% for the Registry), and there was no bias in deaths lost
by type of intervention. Consequently, we do not feel that the
findings reported here are substantially different than they
would have been if out-of-state deaths could have been
captured.
It should also be noted that not all vessels may have been
completely revascularized. Previous studies have shown that
long-term outcomes may be related to the completeness of
revascularization, which in certain instances may be more
achievable with CABG surgery because of the increased
technical ability to revascularize total occlusions, particularly
in patients with three-vessel disease. However, the complete-
ness of revascularization in both CABG surgery and angio-
plasty is an operator choice that involves balancing the safety
of the procedure with its long-term effectiveness, and this study
presents the results of those decisions.
Another caveat is that the primary end point used in this
study was all-cause mortality. Cardiac deaths were impossible
to obtain because autopsy data were not available, and the
“cause of death” field in the death file is not believed to be
sufficiently accurate for identifying cardiovascular deaths. Also,
we were unable to obtain information on restenosis that did
not result in revascularization and we did not identify whether
revascularization was performed on repeat target vessels or on
new vessels. Furthermore, subsequent revascularization was
analyzed without adjusting for patients’ preprocedural risk. All
three of these topics are worthy of future studies, although
restenosis without revascularization cannot be investigated
with the current New York database. Future studies will
address the other topics as well as update this study to reflect
the impact of procedural improvements.
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